Effectiveness of BBIBP-CorV, BNT162b2 and mRNA- 1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: a retrospective cohort study

Página de ítem simple
cic.isFulltextSI
cic.isPeerReviewedtrue
cic.lugarDesarrolloUniversidad Nacional de La Plata
cic.lugarDesarrolloMinisterio de Salud (provincia de Buenos Aires)
cic.lugarDesarrolloUniversidad de Buenos Aires
cic.lugarDesarrolloHospital Interzonal de Agudos Especializado en Pediatría "Sor María Ludovica"
cic.parentTypeArtículo
cic.versionPublicada
dc.date.accessioned2023-03-22T16:27:26Z
dc.date.available2023-03-22T16:27:26Z
dc.identifier.urihttps://digital.cic.gba.gob.ar/handle/11746/11768
dc.titleEffectiveness of BBIBP-CorV, BNT162b2 and mRNA- 1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: a retrospective cohort studyen
dc.typeArtículo
dcterms.abstractBackground Although paediatric clinical presentations of COVID-19 are usually less severe than in adults, serious illness and death have occurred. Many countries started the vaccination rollout of children in 2021; still, information about effectiveness in the real-world setting is scarce. The aim of our study was to evaluate vaccine effectiveness (VE) against COVID-19-associated-hospitalisations in the 3−17-year population during the Omicron outbreak. Methods We conducted a retrospective cohort study including individuals aged 3−17 registered in the online vaccination system of the Buenos Aires Province, Argentina. mRNA-1273 and BNT162b2 were administered to 12−17- year subjects; and BBIBP-CorV to 3−11-year subjects. Vaccinated group had received a two-dose scheme by 12/1/ 2021. Unvaccinated group did not receive any COVID-19 vaccine between 12/14/2021 and 3/9/2022, which was the entire monitoring period. Vaccine effectiveness (VE) against COVID-19-associated hospitalisations was calculated as (1-OR)x100. Findings By 12/1/2021, 1,536,435 individuals aged 3−17 who had received zero or two doses of SARS-CoV-2 vaccines were included in this study. Of the latter, 1,440,389 were vaccinated and 96,046 not vaccinated. VE were 78.0% [68.7−84.2], 76.4%[62.9−84.5] and 80.0%[64.3−88.0] for the entire cohort, 3−11-year (BBIBP-CorV) subgroup and 12−17 (mRNA vaccines) subgroup, respectively. VE for the entire population was 82.7% during the period of Delta and Omicron overlapping circulation and decreased to 67.7% when Omicron was the only variant present. Interpretation This report provides evidence of high vaccine protection against associated hospitalisations in the paediatric population during the Omicron outbreak but suggests a decrease of protection when Omicron became predominant. Application of a booster dose in children aged 3−11-year warrants further consideration.en
dcterms.creator.authorGonzález, Soledad
dcterms.creator.authorOlszevicki, Santiago
dcterms.creator.authorGaiano, Alejandra
dcterms.creator.authorVarela Baino, Ana Nina
dcterms.creator.authorRegairaz, Lorena
dcterms.creator.authorSalazar, Martín
dcterms.creator.authorPesci, Santiago
dcterms.creator.authorMarín, Lupe
dcterms.creator.authorGonzález Martínez, Verónica V.
dcterms.creator.authorVarela, Teresa
dcterms.creator.authorCeriani, Leticia
dcterms.creator.authorGarcía, Enio
dcterms.creator.authorKreplak, Nicolás
dcterms.creator.authorNavarro, Alexia
dcterms.creator.authorEstenssoro, Elisa
dcterms.creator.authorMarsico, Franco
dcterms.isPartOf.issuevol. 13
dcterms.isPartOf.seriesThe Lancet Regional Health – Americas
dcterms.issued2022-09
dcterms.languageInglés
dcterms.licenseAttribution-NonCommercial-NoDerivatives 4.0 International (BY-NC-ND 4.0)
dcterms.subjectCOVID-19en
dcterms.subjectVaccinesen
dcterms.subjectBBIBP-CorVen
dcterms.subjectBNT162b2en
dcterms.subjectmRNA-1273en
dcterms.subject.materiaCiencias Médicas y de la Salud

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Effectiveness of BBIBP-CorV.pdf-PDFA.pdf
Tamaño:
1.57 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
3.46 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos, Informes y presentaciones en Congresos